MOR - モ―ニングスタ― （MorphoSys AG）

https://www.investing.com/news/pro/jpmorgan-downgrades-morphosys-ag-to-underweight-432SI-2971977

https://www.investing.com/news/pro/goldman-sachs-reiterates-sell-rating-on-morphosys-ag-432SI-2968883

MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR) said that its Chief Financial Officer and Management Board member, Sung Lee, has decided to leave the company to move back to California for personal rea…

EQS-News: MorphoSys AG / Key word(s): Miscellaneous Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 20.12.2022 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, December 20, 2022

MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR, MPSYY.PK) reported results from analyses of the ongoing MANIFEST study, a phase 2 clinical trial of pelabresib in patients with myelofibrosis, a type of …

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT).MorphoSys'' Management team will host a …

DGAP-News: MorphoSys AG / Key word(s): Quarter Results Invitation to MorphoSys'' First Quarter 2022 Financial Results Conference Call on May 5, 2022 28.04.2022 / 22:03 The issuer is solely responsible for the content of this announcement.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J''s Janssen Unit Initiates Large-Scale Study of Psoriasis Drug In People of Color Johnson & Johnson''s (NYSE: JNJ ) Janssen unit announced the initiation of VISIBLE, a large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp PsO. The study will further evaluate the efficacy and safety of Tremfya in people of color to generate additional data and provide valuable information about disease burden and the psoriatic disease patient journey in this population. MorphoSys, Incyte Announce Temporary Approval For Blood Cancer Combo Therapy In Switzerland MorphoSys AG (NASDAQ: MOR ) and partner Incyte Corporation (NASDAQ: INCY ) announced that the Swiss agency for therapeutic products has granted temporary approval for Minjuvi, in combination with Bristol-Myers Squibb Company''s (NYSE: BMY ) Revlimid, followed by Minjuvi monotherapy. The regimen is meant for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma, after at least one prior line of systemic therapy including an anti-CD20 antibody, who are not eligible for autologous stem cell transplant.

MOR earnings call for the period ending December 31, 2021.

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operati…

(PR-inside.com) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pursue other opportunities. Following Dr. Wandeler''s departure, the commercial organization led by Joe Horvat, U.S. General Manager, will report directly to the Chief Executive Officer, Jean-Paul Kress, M.D. Dr. Wandeler joined MorphoSys in May 2020 and has been responsible for all commercialization activities worldwide, with a focus on strengthening U.S. operations and the launch of MorphoSys'' targeted immunotherapy ..

MorphoSys AG (NASDAQ: MOR ) presented interim results from the M-PLACE Phase 1b/2a study with felzartamab at the 2021…

MorphoSys AG (NASDAQ: MOR ) presented interim results from the M-PLACE Phase 1b/2a study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN). Felzartamab is a fully human IgG1 monoclonal anti-CD38 antibody that can potentially deplete CD38-positive plasma cells that produce and secrete destructive autoantibodies. Depleting those … Full story available on Benzinga.com

Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathyPLANEGG/MUNICH, GERMANY / ACCESSWIRE / Novemb